Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 1/20 | 0.48 |
| ▸ | PYGM | P11217 | 3/20 | 0.47 |
| ▸ | TK2 | O00142 | 2/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | TYMP | P19971 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18503558 | 0.90 | PYGM (0.58) | DNPH1PYGMTK2P2RY2TYMP | |
| SCHEMBL41270 | 0.90 | PYGM (0.58) | DNPH1PYGMTK2P2RY2TYMP | |
| SCHEMBL63573 | 0.90 | PYGM (0.58) | DNPH1PYGMTK2P2RY2TYMP | |
| SCHEMBL14853731 | 0.90 | PYGM (0.58) | DNPH1PYGMTK2P2RY2TYMP | |
| SCHEMBL18573807 | 0.90 | PYGM (0.58) | DNPH1PYGMTK2P2RY2TYMP | |
| SCHEMBL18512960 | 0.90 | PYGM (0.58) | DNPH1PYGMTK2P2RY2TYMP | |
| SCHEMBL18464475 | 0.89 | PYGM (0.49) | DNPH1PYGMTK2P2RY2P2RY6 | |
| SCHEMBL3470678 | 0.87 | DNPH1 (0.53) | DNPH1PYGMP2RY6P2RY14NT5E | |
| SCHEMBL16807578 | 0.84 | DNPH1 (0.44) | DNPH1PYGMTK2P2RY2P2RY6 | |
| SCHEMBL3470573 | 0.84 | DNPH1 (0.72) | DNPH1P2RY2P2RY6P2RY14NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2640852-A1 | SIGNAL AMPLIFICATION | Speedx Pty Ltd (AU) | 2013-09-25 | — | — | EP | claimed |
| US-8394946-B2 | Multicomponent nucleic acid enzymes and methods for their use | SPEEDX PTY LTD (AU) | 2013-03-12 | — | — | US | claimed |
| WO-2012065231-A1 | SIGNAL AMPLIFICATION | SPEEDX PTY LTD (AU) | 2012-05-24 | — | — | WO | claimed |
| EP-1948822-A1 | MULTICOMPONENT NUCLEIC ACID ENZYMES AND METHODS FOR THEIR USE | JOHNSON & JOHNSON RESEARCH PTY LIMITED (AU) | 2008-07-30 | — | — | EP | claimed |
| US-20070231810-A1 | Multicomponent nucleic acid enzymes and methods for their use | SPEEDX PTY LTD (AU) | 2007-10-04 | — | — | US | claimed |
| WO-2007041774-A1 | MULTICOMPONENT NUCLEIC ACID ENZYMES AND METHODS FOR THEIR USE | JOHNSON & JOHNSON RESEARCH PTY LIMITED (AU) | 2007-04-19 | — | — | WO | claimed |
| WO-2026102473-A1 | TEMPERATURE DEPENDENT PROBES FOR TARGET DETECTION | SPEEDX PTY LTD (AU) | 2026-05-21 | — | — | WO | disclosed |
| EP-4713476-A1 | TARGET DETECTION USING TEMPERATURE CONTROLLED PROBES | Speedx Pty Ltd (AU) | 2026-03-25 | — | — | EP | disclosed |
| EP-3610036-B1 | DETECTION CASCADES | SPEEDX PTY LTD (AU) | 2025-07-02 | — | — | EP | disclosed |
| US-12163182-B2 | Multiplex detection of nucleic acids | SPEEDX PTY LTD (AU) | 2024-12-10 | — | — | US | disclosed |
| WO-2024234030-A1 | TARGET DETECTION USING TEMPERATURE CONTROLLED PROBES | SPEEDX PTY LTD (AU) | 2024-11-21 | — | — | WO | disclosed |
| US-12123051-B2 | Nucleic acid ratio determination | SPEEDX PTY LTD (AU) | 2024-10-22 | — | — | US | disclosed |
| CN-111492434-B | Determination of nucleic acid ratio | 斯皮德斯私人有限公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-1512748-A1 | O-methyltransferases of tetrahydrobenzylisoquinoline alkaloid biosynthesis in papaver somniferum | Johnson & Johnson Research Pty Limited (AU) | 2005-03-09 | — | — | EP | disclosed |
| EP-1401853-A4 | MODULATORS OF PHARMACOLOGICAL AGENTS | UNIV DUKE (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1401853-A1 | MODULATORS OF PHARMACOLOGICAL AGENTS | DUKE UNIVERSITY (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030083294-A1 | Enhancing or inhibiting the biological activity of nucleic acid ligands by administrating a modulator, to change the binding of the nucleic acid ligand for its target or degrading or cleaving | REGADO BIOSCIENCES, INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2002096926-A1 | MODULATORS OF PHARMACOLOGICAL AGENTS | DUKE UNIVERSITY (US) | 2002-12-05 | — | — | WO | disclosed |
| US-20020137135-A1 | Novel NPG-1 gene that is differentially expressed in prostate tumors | BETH ISRAEL DEACONESS MEDICAL CENTER, INC., A MASSACHUSETTS CORPORATION | 2002-09-26 | — | — | US | disclosed |
| US-6287777-B1 | SEVERAL GENES EXPRESSED DIFFERENTIALLY BETWEEN THE HUMAN PROSTATE CARCINOMA CELL LINES LNCAP AND PC-3, WHICH ARE ANDROGEN-DEPENDENT AND ANDROGEN-INDEPENDENT, RESPECTIVELY, HAVE NOW BEEN ISOLATED. ONE OF THESE GENES, DESIGNATED NPG-1. | BETH ISRAEL DEACONESS MEDICAL CENTER | 2001-09-11 | — | — | US | disclosed |